Treatment advances in systemic juvenile idiopathic arthritis.
about
IL-1 Inhibition in Systemic Juvenile Idiopathic ArthritisSafety of tocilizumab in the treatment of juvenile idiopathic arthritis.The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohortEffect of miR-19a and miR-21 on the JAK/STAT signaling pathway in the peripheral blood mononuclear cells of patients with systemic juvenile idiopathic arthritis.Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.Management of Juvenile Idiopathic Arthritis: A Clinical Guide.New frontiers in the treatment of systemic juvenile idiopathic arthritis.Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.[Still's disease in children and adults].IL1RN Variation Influences both Disease Susceptibility and Response to Human Recombinant IL-1RA Therapy in Systemic Juvenile Idiopathic Arthritis.The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON).The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications
P2860
Q28078134-14E5111E-17C2-43DD-BF5F-45A8067D7660Q30235357-95224FA7-92B3-47EA-B4D1-C7FE5307D059Q31033140-F7C46021-4E3A-464F-927F-24D75269B8F4Q36953886-5884351A-0212-4424-9C9E-3F3DC8A94D22Q37195338-A7D6EE6B-3B1C-4A85-820A-2B51F74DDD5DQ37235737-610F7F3C-A09D-4C79-88E1-1E14B8A363B5Q37274470-4E87ADEC-5305-4C19-B296-0A778A605C3AQ38916421-38279B01-A0E9-4E73-8A75-52F253804E24Q39424746-12A75E29-9ED6-4540-A666-63A7B82F3EE0Q39663220-C68388DF-4A15-4D95-B4D0-7D42872873D6Q40045645-885CA83A-7DC7-4DD4-B624-296645B83AEBQ52612756-A49FE9E2-420A-47C9-9CEC-04A5463D7023Q55192377-53A2FFAD-A8E3-4BAF-A9E4-1334CAB68D50Q55206915-D0E2627D-7BEE-479D-AB99-E3A98FF2BF03Q57304542-BE3D8214-B41B-4301-9881-EFFF14822C31
P2860
Treatment advances in systemic juvenile idiopathic arthritis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Treatment advances in systemic juvenile idiopathic arthritis.
@en
type
label
Treatment advances in systemic juvenile idiopathic arthritis.
@en
prefLabel
Treatment advances in systemic juvenile idiopathic arthritis.
@en
P2860
P356
P1433
P1476
Treatment advances in systemic juvenile idiopathic arthritis.
@en
P2093
Timothy Beukelman
P2860
P356
10.12703/P6-21
P577
2014-04-01T00:00:00Z